Indeed, results from in vivo models show that neutralizing IL-6 enhances the therapeutic effect of paclitaxel in an ovarian cancer mouse model, leading to reduced tumor growth and angiogenesis [47]. Here, IL6 is linked to ovarian carcinoma.